# Cardiovascular Risk of Antiretroviral Therapy Drugs in HIV

> **NIH HL R01** · OKLAHOMA MEDICAL RESEARCH FOUNDATION · 2026 · $654,015

## Abstract

PROJECT SUMMARY
Although antiretroviral therapy drugs (ART) have prevented HIV propagation and increased life expectancy of
people with HIV (PWH), the rate of sudden death in this population is 2-4-times higher than people without HIV.
Autopsies have revealed cardiac fibrosis in half of this HIV patient population, a likely etiology for sudden death.
The protease inhibitor class ART (PI-ART) is linked to cardiovascular risk in PWH, and it is plausible that ART
can exacerbate the risk by inducing cardiac fibrosis. Our long-term goals are to determine the mechanism and the
impact of ART-induced cardiac fibrosis in PWH, and to explore preventive strategies. Transforming growth factor β1
(TGFβ1) is a strong profibrotic cytokine and platelets contain ~100 times more TGFβ1 than other cells and are a
major source of plasma TGFβ1 contributing to organ fibrosis. Higher plasma TGFβ1 levels and cardiac fibrosis are
observed in HIV+ individuals, but whether ART further increases plasma TGFβ1 and cardiac fibrosis in PWH is
not clear. In pilot studies, we observed that newer ART regimens, including PI-boosted dose of ritonavir (RTV) and
tenofovir, activated platelets to release TGFβ1, which can be blocked by Ceefourin-1, a specific inhibitor of MRP4,
a membrane transporter highly expressed in platelets from HIV patients. Injection of a PI-boosted dose of RTV
in transgenic Tg26 HIV mice (which exhibit multiple HIV-associated comorbidities) increased cardiac fibrosis and
diastolic dysfunction associated with the accumulation of CD206+ cells expressing αSMA in the heart,
presumably macrophages. These results led to our central hypothesis that ART may activate platelets to release
TGFβ1 via MRP4, which stimulates macrophages to undergo mesenchymal transition, inducing cardiac fibrosis.
The objective of this application is to determine the mechanism by which different classes of ART induce platelet
TGFβ1 release and identify the cell types to which TGFβ1 signals, leading to cardiac fi

## Key facts

- **NIH application ID:** 11310194
- **Project number:** 5R01HL167656-04
- **Recipient organization:** OKLAHOMA MEDICAL RESEARCH FOUNDATION
- **Principal Investigator:** Jasimuddin  Ahamed
- **Activity code:** R01 (R01, R21, SBIR, etc.)
- **Funding institute:** HL
- **Fiscal year:** 2026
- **Award amount:** $654,015
- **Award type:** 5
- **Project period:** 2023-04-01T00:00:00 → 2027-03-31T00:00:00

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/11310194

## Citation

> US National Institutes of Health, RePORTER application 11310194, Cardiovascular Risk of Antiretroviral Therapy Drugs in HIV (5R01HL167656-04). Retrieved via AI Analytics 2026-06-30 from https://api.ai-analytics.org/grant/nih/11310194. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*